Icaritin
- Generic Name
- Icaritin
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O6
- CAS Number
- 118525-40-9
- Unique Ingredient Identifier
- UFE666UELY
- Background
Icaritin has been used in trials studying the treatment of Solid Tumors, Metastatic Breast Cancer, and Hepatocellular Carcinoma (HCC).
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Zhiyong Huang
- Target Recruit Count
- 60
- Registration Number
- NCT06896396
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma(HCC)
- Interventions
- Drug: FOLFOX4Procedure: HAICProcedure: Local treatmentDrug: The original treatment regimen
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanjing Tianyinshan Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06893887
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06825546
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06285149
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06269445
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: TACE（transcatheter arterial chemoembolization）
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05903456
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 261
- Registration Number
- NCT05594927
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Chifeng Municipal Hospital, Chifeng, Mongolia, China
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 89
- Registration Number
- NCT03236649
- Locations
- 🇨🇳
First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- Conditions
- Advanced HBV-Related Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: HUACHANSU PIAN
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 312
- Registration Number
- NCT03236636
- Locations
- 🇨🇳
Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳The Sixth People's Hospital in Shenyang, Shenyang, Liaoning, China
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT02496949
- Locations
- 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.